Enhancing CAR-T therapy development: harnessing cell selection flexibility

Clinical advancements in personalized cell therapy, particularly CAR-T cell therapy, have created a demand for innovative, closed, automated, and space-efficient manufacturing methods. Given that each therapeutic product requires a unique manufacturing process, flexibility in automation platforms is essential to accommodate these varying needs. This article will explore recent developments in the Cocoon® Platform, an automated system for CAR-T manufacturing, highlighting the ability to adapt to different processes including positively or negatively selecting T cells directly from apheresis. Enabling direct cell isolation from the input material eliminates the need for additional upstream processing equipment, thus reducing costs, time, and space requirements. Automatic transfer to an expansion chamber for extended culture enables further reduction in manual processing.